EU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industry

With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.

One of the European Commissions Vice-Presidents, Margaritis Schinas (left), presented the HERA proposal on Thursday, alongside with Commissioner for Health and Food Safety Stella Kyriakides and Commissioner for Internal Market Thierry Breton. | Photo: FRANCOIS WALSCHAERTS/AFP / AFP

Covid-19 has brought many hard-learned lessons, both financial and human. Hence, a new deparment to anticipate and fend off future health emergencies is being established on European soil as early as next year.

This was the overall message when the EU Commission on Thursday released its proposal for the future European health agency, the Health Emergency Preparedness and Response Authority (HERA), which will already be operational from from the beginning of 2022.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs